Amiodarone is useful in the treatment of patients with ventricular arrhythmias after acute myocardial infarction and was equally useful when these arrhythmias were associated with CHF. Amiodarone prolongs repolarization and lowers heart rate, actions that are beneficial in treating symptomatic arrhythmias. The absence of proarrhythmic effects distinguishes amiodarone from other antiarrhythmic agents. No excess mortality was seen in any of the amiodarone trials, and in fact, a definite trend toward a decrease in the number of sudden deaths was noted. For many years, amiodarone has been the antiarrhythmic drug of choice in Europe. Only in recent years has this drug gained respectability in the United States. Amiodarone is truly a late comer to our shores.
Articles| May 01 1997
- Views Icon Views
- Share Icon Share
LG Futterman, L Lemberg; Amiodarone: a late comer. Am J Crit Care 1 May 1997; 6 (3): 233–239. doi: https://doi.org/10.4037/ajcc1918.104.22.168
Download citation file: